Sofinnova Investments’s Inozyme Pharma INZY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-4,280,308
| Closed | -$17.1M | – | 66 |
|
|
2025
Q2 | $17.1M | Hold |
4,280,308
| – | – | 1.05% | 28 |
|
|
2025
Q1 | $3.9M | Hold |
4,280,308
| – | – | 0.25% | 53 |
|
|
2024
Q4 | $11.9M | Hold |
4,280,308
| – | – | 0.86% | 29 |
|
|
2024
Q3 | $22.4M | Hold |
4,280,308
| – | – | 1.78% | 18 |
|
|
2024
Q2 | $19.1M | Hold |
4,280,308
| – | – | 0.99% | 33 |
|
|
2024
Q1 | $32.8M | Hold |
4,280,308
| – | – | 1.83% | 21 |
|
|
2023
Q4 | $18.2M | Hold |
4,280,308
| – | – | 1.02% | 26 |
|
|
2023
Q3 | $18M | Buy |
4,280,308
+625,000
| +17% | +$3.18M | 1.13% | 25 |
|
|
2023
Q2 | $20.4M | Hold |
3,655,308
| – | – | 1.33% | 20 |
|
|
2023
Q1 | $20.9M | Hold |
3,655,308
| – | – | 1.34% | 23 |
|
|
2022
Q4 | $3.84M | Hold |
3,655,308
| – | – | 0.23% | 40 |
|
|
2022
Q3 | $9.8M | Hold |
3,655,308
| – | – | 0.57% | 32 |
|
|
2022
Q2 | $17.4M | Buy |
3,655,308
+1,627,000
| +80% | +$7.08M | 1.45% | 18 |
|
|
2022
Q1 | $8.3M | Hold |
2,028,308
| – | – | 0.63% | 34 |
|
|
2021
Q4 | $13.8M | Hold |
2,028,308
| – | – | 0.81% | 31 |
|
|
2021
Q3 | $23.5M | Hold |
2,028,308
| – | – | 1.39% | 16 |
|
|
2021
Q2 | $34.6M | Hold |
2,028,308
| – | – | 1.99% | 12 |
|
|
2021
Q1 | $40.2M | Hold |
2,028,308
| – | – | 2.41% | 10 |
|
|
2020
Q4 | $41.9M | Hold |
2,028,308
| – | – | 2.49% | 8 |
|
|
2020
Q3 | $53.3M | Buy |
+2,028,308
| New | +$50.4M | 3.95% | 5 |
|
Sofinnova Investments's INZY Position: Q3 2025 in Review
Sofinnova Investments sold out of Inozyme Pharma (INZY) in Q3 2025, closing a stake of 4,280,308 shares — an estimated $17.1M sold.
Sofinnova Investments first reported a position in INZY in Q3 2020 and held it in 20 quarters. The position peaked at $53.3M in Q3 2020. 0 funds tracked by Wall St. Rank hold INZY as of Q3 2025.
- Sofinnova Investments reported no remaining Inozyme Pharma position as of Q3 2025 after selling out during the quarter.
- Sofinnova Investments sold 4,280,308 Inozyme Pharma shares in Q3 2025, an estimated $17.1M.
- Sofinnova Investments first reported a position in Inozyme Pharma in Q3 2020 and held it in 20 quarters.
- Sofinnova Investments's Inozyme Pharma position peaked at $53.3M in Q3 2020.
- 0 funds tracked by Wall St. Rank held Inozyme Pharma as of Q3 2025.
Based on Sofinnova Investments's 13F filing for Q3 2025, filed 14 Nov 2025.